Compass Therapeutics Financial Statements
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Compass Therapeutics revenue and earnings
In fiscal 2025, Compass Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 9 years shown. Compass Therapeutics reported a net loss of $66.5 million, compared with a loss of $49.4 million a year earlier.
Summary generated from market data by MetaCap's automated system. Methodology
Compass Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20202020-03-31 | FY 20192019-12-31 | FY 20192019-03-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 850.00K | 0 | — | — | — | — | — | — |
| Revenue growth (YoY) | -100.00% | — | — | — | — | — | — | — | — |
| Operating Expenses | 72.84M | 57.48M | 50.36M | 41.66M | 81.88M | 27.81M | — | 34.05M | — |
| Research & Development | 55.97M | 42.34M | 38.12M | 30.00M | 20.34M | 14.90M | — | 22.45M | — |
| Operating Income | -72.84M | -56.63M | -50.36M | -41.66M | -81.88M | -27.81M | -32.10K | -34.05M | -32.76K |
| Interest Expense | — | — | — | 0 | 370.00K | 908.00K | 5.38K | 1.23M | 3.28K |
| Other Income (Expense) | 6.35M | 7.25M | 7.87M | 2.43M | -299.00K | -1.66M | — | -601.00K | — |
| Pretax Income | — | — | -42.49M | -39.23M | -82.18M | -29.47M | — | -34.65M | — |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 32.00K | — | 91.00K | — |
| Net Income | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M | -29.50M | -37.48K | -34.74M | -36.04K |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.42 | -0.36 | -0.33 | -0.37 | -1.31 | -0.96 | -0.01 | -5.19 | -0.01 |
| EPS (Diluted) | — | — | — | — | -1.31 | -0.96 | -0.01 | -5.19 | -0.01 |
| Shares Outstanding (Basic) | 157.69M | 137.38M | 127.03M | 105.19M | 62.87M | 30.78M | 5.00M | 6.69M | 5.00M |
| Shares Outstanding (Diluted) | — | 137.40M | — | — | 62.87M | 30.78M | 5.00M | 6.69M | 5.00M |
| EBITDA | -72.56M | -56.04M | -49.66M | -40.87M | -81.28M | -25.41M | — | -31.95M | — |
| Operating Margin | — | -6661.76% | — | — | — | — | — | — | — |
| Net Margin | — | -5808.82% | — | — | — | — | — | — | — |
This table shows 9 annual periods of Compass Therapeutics's income statement, from FY 2025 back to FY 2019, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow CMPX's reporting calendar. What is a income statement?